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Background. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study, a randomized controlled cancer prevention
trial, showed a 32% reduction in prostate cancer incidence in response to vitamin E supplementation. Two other trials were not
confirmatory, however. Objective. We compared the change in serum metabolome of the ATBC Study participants randomized to
receive vitamin E to those who were not by randomly selecting 50 men from each of the intervention groups (50mg/day all-rac-𝛼-
tocopheryl acetate (ATA), 20mg/day 𝛽-carotene, both, placebo).Methods. Metabolomic profiling was conducted on baseline and
follow-up fasting serum (Metabolon, Inc.). Results. After correction for multiple comparisons, five metabolites were statistically
significantly altered (𝛽 is the change in metabolite level expressed as number of standard deviations on the log scale): 𝛼-CEHC
sulfate (𝛽 = 1.51, 𝑝 = 1.45 × 10−38), 𝛼-CEHC glucuronide (𝛽 = 1.41, 𝑝 = 1.02 × 10−31), 𝛼-tocopherol (𝛽 = 0.97, 𝑝 = 2.22 ×
10−13), 𝛾-tocopherol (𝛽 = −0.90, 𝑝 = 1.76 × 10−11), and 𝛽-tocopherol (𝛽 = −0.73, 𝑝 = 9.40 × 10−8). Glutarylcarnitine, beta-
alanine, ornithine, and N6-acetyllysine were also decreased by ATA supplementation (𝛽 range 0.40 to −0.36), but not statistically
significantly.Conclusions. Comparison of the observedmetabolite alterations resulting fromATA supplementation to those in other
vitamin E trials of different populations, dosages, or formulations may shed light on the apparently discordant vitamin E-prostate
cancer risk findings.
1. Introduction
Vitamin E is a family of compounds that has long been
thought to have biological properties that may prevent
prostate and other cancers [1]. Of these compounds, 𝛼-
tocopherol is the most bioavailable in humans and, according
to the Institute of Medicine, is the only form of vitamin E that
has been demonstrated to reverse vitamin E deficiency and is
the most predominant form that is maintained in plasma and
tissues [2]. Thus, 𝛼-tocopherol is the most thoroughly exam-
ined with respect to its potential beneficial health effects.
The Alpha-Tocopherol, Beta-Carotene Cancer Prevention
(ATBC) Study, a large randomized controlled trial of vitamin
E and 𝛽-carotene supplementation in male Finnish smokers,
found that vitamin E supplementation led to 32% lower
prostate cancer incidence, particularly of more aggressive
disease [3]. Results from two subsequent large controlled
trials were not confirmatory, however, with the Selenium and
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Vitamin E Cancer Prevention Trial (SELECT) finding 17%
higher prostate cancer incidence in men given vitamin E [4]
and the Physicians’Health Study II (PHS II) showing no effect
of vitaminE supplementation [5]. Several explanations for the
divergent trial findings include the substantial difference in
the 𝛼-tocopherol dose (ranging from 50 IU to 400 IU daily)
and possible selective vitamin E-prostate cancer protective
effects in cigarette smokers or for more advanced disease.
Biologic mechanisms have also been investigated, including
alterations in circulating androgens or vascular endothelial
growth factors [6, 7], yet our understanding of the effects of
𝛼-tocopherol supplementation on risk of developing cancer
remain incomplete.
Metabolomic profiling is a relatively new laboratory
analytical tool that measures an array of low molecular
weight biochemicals in a variety of matrices including blood
[8]. Agnostic approaches such as genome-wide association
studies have discovered new biological associations between
specific genes or their biologic pathways and human disease,
including cancer, as well as other phenotypes. Similarly,
examination of the human metabolome offers the potential
to discover molecular species relevant to various diseases [9–
11], characteristics (e.g., energy balance and BMI) [12], and
environmental exposures (e.g., diet, smoking, and vitamin
supplementation) [13, 14]. Metabolomic profiling may also
help elucidate how vitamin E supplementation impacted
prostate cancer incidence in the aforementioned trials [15].
To our knowledge, only two studies have examined the
biological response to supplementation with 𝛼-tocopherol in
healthy individuals and both had very small sample sizes
(𝑛 = 10) and short durations of supplementation (2 and
4 weeks, resp.) [16, 17]. One additional study examined
patients with nonalcoholic steatohepatitis (NASH) who had
been randomized to vitamin E or placebo and compared
those whose disease responded to vitamin E to those who
did not respond; this study also had a small sample size
(𝑛 = 16 in each group) [18]. Our understanding of the
biochemical effects of long-term 𝛼-tocopherol supplementa-
tion therefore remains incomplete. In the present study, we
quantitatively examined the pre- and postenrollment fasting
serum metabolome of 100 men randomized to receive long-
term 𝛼-tocopherol supplementation and 100 men who did
not receive 𝛼-tocopherol in the ATBC Study.
2. Methods
2.1. Study Population. The ATBC Study was a double-blind,
placebo-controlled cancer prevention trial designed to test
whether supplementation with 𝛼-tocopherol or 𝛽-carotene
influenced cancer incidence [19]. Participants were recruited
between 1985 and 1988 in southwestern Finland and were
males between the ages of 50–69 years old and who smoked
at least 5 cigarettes per day at enrollment. Trial participants (𝑛
= 29,133) were randomized to one of four groups based on a
2 × 2 factorial design: (1) 𝛼-tocopherol (all-rac-𝛼-tocopheryl
acetate (ATA), 50mg/day), (2) 𝛽-carotene (20mg/day), (3)
both supplements, or (4) placebo. Supplementation contin-
ued for 5–8 years until the trial ended on April 30, 1993.
Compliance which was estimated on the basis of residual
capsule counts was excellent, with 80% of participants taking
more than 95%of their capsules [19]. Overnight fasting blood
samples were collected from all participants at baseline, and
on-study samples were collected annually from a random
sample of participants. The blood samples were processed
to serum, aliquoted, and stored at −70∘C. The ATBC Study
was approved by institutional review boards at both the US
National Cancer Institute and the Finnish National Public
Health Institute; written informed consentwas obtained from
all trial participants.
For the present analysis, 50 men were randomly sampled
from each trial intervention group for a total sample of 200
individuals; participants were classified as either receiving the
trial 𝛼-tocopherol supplement (i.e., ATA alone or ATA plus
𝛽-carotene) or not (i.e., placebo or 𝛽-carotene alone). Men
included in the current study sample had to (1) have both pre-
and postrandomization fasting serum sample available with
the follow-up sample collected at least 1 year after the baseline
blood collection (mean = 3.3 years, range 1.0–6.9 years) and
start of supplementation and (2) be cancer-free for at least 5
years after the follow-up blood collection. We required the
participants to be cancer-free for 5 years after follow-up blood
collection to minimize the possibility of reverse causation,
that is, changes in the circulating metabolome resulting from
undiagnosed cancer.
2.2. Metabolomic Analysis. Metabolomic profiling was con-
ducted on baseline and follow-up serum samples at Met-
abolon, Inc. (Durham, NC), using an untargeted analysis
capturing a broad array of low molecular weight compounds
as described in detail previously [13, 20]. Briefly, samples
were extracted and prepared for either UPLC/MS/MS2 or
GC/MS. Raw data was extracted, peak-identified, and QC
processed as described previously [20, 21]. For QA/QC
purposes, additional samples were included with each day’s
analysis including extracts of a pool of well-characterized
human serum, extracts of a pool created from a small aliquot
of the experimental samples, and process blanks. QC samples
were spaced evenly among the injections and all experimen-
tal samples were randomly distributed throughout the run
with baseline and follow-up samples from each individual
analyzed in the same batch. The median and interquartile
range of the intraclass correlation coefficient (ICC) across the
metabolites was 0.84 (0.52–0.96); these ICCs are similar to
those seen previously in samples analyzed by this laboratory
[22].
A total of 516 compounds were identified in our samples;
any compound with more than three missing observations in
either the baseline or follow-up sample was excluded, leaving
500 metabolites for analysis. Metabolites were then grouped
into 9 mutually exclusive chemical classes (amino acids,
carbohydrates, cofactors and vitamins, energy metabolites,
lipids, nonstandard amino acids, nucleotides, peptides, and
xenobiotics) based on the available literature [21].
2.3. Statistical Analysis. In order to account for batch
variability, metabolite levels were divided by their batch’s
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Age (years) 57.5 (4.9) 57.8 (5.0) 0.70
Height (cm) 174 (5.9) 174 (6.6) 0.91
Weight (kg) 79.6 (10.7) 78.4 (12.5) 0.40
BMI (kg/m2) 26.2 (3.2) 25.8 (3.5) 0.36
Cigarettes per day 20.3 (9.9) 19.8 (8.9) 0.80
Years of smoking 35.1 (9.6) 35.7 (9.5) 0.68
Quit smoking at follow-up visit (%) 29.0 22.0 0.21
Physically active (%) 23.0 25.0 0.74
>Elementary school education (%) 29.0 23.0 0.33
Dietary intake per day
Total energy (kcal) 2,775 (691) 2,763 (695) 0.60
Fruit (g) 235 (204) 226 (161) 0.80
Vegetables (g) 305 (113) 319 (130) 0.80
Red meat (g) 75.0 (31.4) 75.6 (29.3) 0.71
Alcohol (ethanol, g) 13.5 (16.8) 14.7 (16.0) 0.19
Serum concentrations
Total cholesterol (mmol/L)
Baseline 6.4 (1.0) 6.4 (1.1) 0.87
Follow-up 6.0 (1.0) 6.3 (1.2) 0.20
ATA (mg/L)
Baseline 12.5 (3.1) 12.1 (2.9) 0.33
Follow-up 12.9 (3.2) 18.3 (4.2) <0.0001
𝛽-Carotene (𝜇g/L)
Baseline 272 (255) 240 (123) 0.76
Follow-up 1,887 (1,886) 2,014 (2,073) 0.72
Retinol (𝜇g/L)
Baseline 576 (107) 585 (122) 0.82
Follow-up 597 (120) 614 (136) 0.41
1All variables are from the baseline questionnaire unless otherwise indicated. Values are means (standard deviation) unless otherwise indicated.
median value. Normalized metabolite levels were then log-
transformed and missing values were imputed to the min-
imum of nonmissing values. In our primary analysis, we
modeled the association between change in log-metabolite
levels and trial assignment (i.e., ATA versus noATA) by linear
regression. Secondary analyses were conducted stratifying by
number of cigarettes smoked per day, alcohol consumption,
duration of supplementation with ATA, trial 𝛽-carotene
supplementation, and baseline serum 𝛼-tocopherol concen-
tration. The threshold for statistical significance for our main
analysis was 0.0001022495 based on a Bonferroni correction
for 500 tests to obtain a Family-Wise-Error-Rate (FWER)
of 0.05 or 0.00021 based on a permutation correction. For
the latter, we calculated the minimum 𝑝 value for each of
10,000 permuted datasets, where we permuted the group
assignment, and found the 0.05 quantile to be 0.00021. We
further examined whether a particular chemical class of
metabolites was over- or underrepresented among our top
metabolites. For this analysis, we categorized metabolites
as below a 𝑝 value of 0.05 (yes/no) and as belonging to
a chemical class (yes/no) and then used Fisher’s exact test
to determine whether the representation among the top
metabolites was statistically significant at the threshold of
0.0056 based on a Bonferroni correction for 9 tests. All anal-
yses were performed using SAS version 9.1.3 (SAS Institute,
Cary, NC).
3. Results
Characteristics of the study population by trial ATA assign-
ment are shown in Table 1. With the exception of 42% higher
serum 𝛼-tocopherol concentrations at follow-up in vitamin E
supplemented men, there were no differences by intervention
arm, as would be expected based on the randomized design
of the ATBC Study.
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Table 2: Metabolites that changed significantly (𝑝 < 0.05) in response to ATA supplementation in the ATBC Study, ranked by statistical
significance (smallest to largest 𝑝 value).
Metabolite Chemical class Number > LOD
∗ at
baseline
Number > LOD∗ at
follow-up Effect size (𝛽)
† 𝑝 value
Alpha-CEHC sulfate Cofactors andvitamins 39 151
1.512 1.45 × 10−38
Alpha-CEHC glucuronide Cofactors andvitamins 4 87
1.412 1.02 × 10−31
Alpha-tocopherol Cofactors andvitamins 200 200
0.974 2.22 × 10−13
Gamma-tocopherol Cofactors andvitamins 196 188
−0.902 1.76 × 10−11
Beta-tocopherol Cofactors andvitamins 199 186 −0.731 9.40 × 10
−8
Fructose Carbohydrate 200 200 0.401 0.0043
Glutarylcarnitine (C5) Amino acid 200 200 −0.400 0.0044
Beta-alanine Amino acid 200 200 −0.386 0.0061
Ornithine Amino acid 200 200 −0.363 0.0100
N6-acetyllysine Amino acid 200 200 −0.357 0.0112
Gamma-glutamylisoleucine Peptide 200 200 −0.332 0.0185
2-Ethylhexanoate Xenobiotics 200 200 0.316 0.0253
Bilirubin (E,Z or Z,E)∗ Cofactors andvitamins 184 190
0.312 0.0268
Seryl-leucine Peptide 179 184 −0.306 0.0300
Gamma-CEHC glucuronide Cofactors andvitamins 90 127 0.303 0.0319
Bradykinin, des-arg(9) Peptide 192 194 0.303 0.0320
Arabinose Carbohydrate 117 165 −0.302 0.0325
3-Hydroxydecanoate Lipid 200 200 0.301 0.0327
Linolenate [alpha or gamma;
(18:3n3 or 6)] Lipid 200 200 0.301 0.0328
Phenylalanylarginine Peptide 133 158 0.297 0.0352
3-Hydroxypropanoate Lipid 200 200 −0.297 0.0355
Inositol 1-phosphate (I1P) Lipid 200 200 0.293 0.0377
5 alpha-androstan-3 alpha,17
beta-diol disulfate Lipid 183 171
0.287 0.0425
Creatinine Amino acid 200 200 −0.277 0.0496
∗LOD = limit of detection.
†Effect size denotes the change in metabolite level (expressed in number of standard deviations on the log scale) for the ATA arm versus the no ATA arm. The
effect size and 𝑝 value were estimated by linear regression.
Table 2 presents findings for the 24 metabolites that
changed in response to the ATA supplementation with a
statistical significance of 𝑝 < 0.05. After correction for
multiple comparisons using a statistical threshold of 𝑝 <
0.00021, five of the 500 metabolites identified in our analysis
changed statistically significantly in response to vitamin E
supplementation, that is, increases in 𝛼-CEHC sulfate, 𝛼-
CEHC glucuronide, and 𝛼-tocopherol and reductions in 𝛾-
tocopherol and 𝛽-tocopherol (Table 2). The strength of these
top vitamin E metabolite associations differed by neither
smoking intensity (i.e., number of cigarettes smoked daily),
with interaction 𝑝 values for 𝛼-CEHC sulfate, 𝛼-CEHC
glucuronide, 𝛼-tocopherol, 𝛾-tocopherol, and 𝛽-tocopherol
of 0.65, 0.11, 0.95, 0.63, and 0.87, respectively, nor subgroups
of duration of ATA supplementation, alcohol consumption,
baseline serum 𝛼-tocopherol concentration, or the trial 𝛽-
carotene supplementation. One other vitamin E metabolite,
gamma-CEHC-glucuronide, wasmoreweakly related toATA
supplementation (beta-0.30).
Beyond the vitamin E-related compounds, the next most
significant metabolites were four structurally similar amino
acids—glutarylcarnitine, beta-alanine, ornithine, and N6-
acetyllysine—that were decreased by ATA supplementation
and shared fairly similar beta-estimates (−0.40 to −0.36)
and fructose that increased in response. These associations
were not, however, formally significant based on the 𝑝
value threshold for multiple comparisons, and there were
no statistically significant interactions between these or
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any other measured metabolites and ATA supplementation
duration, smoking intensity, alcohol consumption, base-
line serum 𝛼-tocopherol concentration, or the 𝛽-carotene
supplement.
Examination of the chemical classes of the top metabo-
lites revealed that the “cofactors and vitamins” class contained
a greater number of significant metabolites (7 of 23, 30%,
𝑝 = 3.45 × 10−5) than would be expected by chance alone.
No other chemical class was over- or underrepresented in
the most statistically significantly associated metabolites (all
𝑝 > 0.10).
4. Discussion
In this randomized controlled trial of male smokers, we iden-
tified five metabolites whose relative concentrations changed
significantly in response to long-term supplementation with
all-rac-𝛼-tocopheryl acetate (ATA). To our knowledge, this is
the largest study and the only one of long-term supplemen-
tation to examine the change in the human serum or plasma
metabolome in response to supplementation with this vita-
min E compound. As anticipated and previously reported, 𝛼-
tocopherol concentrations increased significantly in response
to the ATBC trial vitamin E supplementation, while concen-
trations of 𝛾-tocopherol and 𝛽-tocopherol decreased. Prior
studies have shown such reductions in 𝛾-tocopherol and
𝛽-tocopherol concentrations during 𝛼-tocopherol supple-
mentation [23, 24]. 𝛿-Tocopherol was not detected in our
pre- or postsupplementation samples in either intervention
group.
The two strongest effects on serum metabolites we
observed were substantially elevated concentrations of 𝛼-
CEHC sulfate and 𝛼-CEHC glucuronide. 𝛼-CEHC is an end-
product 𝛼-tocopherol metabolite generated through serial
𝜔-oxidation and 𝛽-oxidation by cytochrome P450 (CYP)
enzymes, particularly CYP4F2, CYP3A4, and CYP3A5,
which may be upregulated by all vitamin E compounds
through activation of the nuclear pregnane X receptor (PXR),
although the role of PXR remains controversial [25, 26].
These metabolic products are subsequently glucuronidated
or sulfated for excretion by UDP-glucuronosyltransferases
(UGT) and sulfatases, respectively [27], which appear to
occur once an individual’s capacity for hepatic incorporation
of 𝛼-tocopherol into low-density lipoprotein (LDL) particles
has been reached. Based on this, circulating 𝛼-CEHC has
been suggested as a biomarker of optimum 𝛼-tocopherol
status [28, 29]. This suggests that the circulating and tissue-
specific concentrations of 𝛼-CEHC and its glucuronide and
sulfate metabolites are dependent upon the dose of 𝛼-
tocopherol administered, as well as an individual’s LDL
concentrations and level of oxidative stress [28]. In fact,
cigarette smoking, which increases the latter, has been asso-
ciated with 𝛼-CEHC concentrations [30]. Interestingly, 𝛼-
CEHC may have independent anticarcinogenic effects that
𝛼-tocopherol does not exhibit, including being strongly anti-
inflammatory [31].Thismay be consistentwith the hypothesis
that the conflicting prostate cancer clinical trial findings for
𝛼-tocopherol supplementation could be due to either the
different vitamin E doses administered or the cigarette smok-
ing status of the trial populations. An inverse association
was observed between vitamin E supplementation and risk
of prostate cancer in the ATBC Study, which administered
50 IU/day and included only men who were current smokers
at enrollment [3]. In contrast, there was no supplement effect
in the PHS II which administered 400 IU every other day
and included mostly nonsmokers [5], and higher prostate
cancer incidence was observed in SELECT among mostly
nonsmoking men receiving 400 IU daily [4]. To our knowl-
edge, neither circulating 𝛼-CEHCnor its conjugated metabo-
lites have been examined in relation to risk of prostate or
other cancers.
Two previous studies of metabolomic profile changes
in response to 𝛼-tocopherol supplementation in healthy
participants did not identify any of the top five serum
metabolites observed here [16, 17], possibly due to one or
more differences in the study methodologies. For example,
both prior studies supplemented participants for only 14 days,
as compared with an average of 3.3 years in the present
analysis. Also, the 𝛼-tocopherol doses and preparations
differed greatly from theATBCStudy, with one administering
400mg of RRR-𝛼-tocopheryl acetate daily [17] and the other
feeding participants 55 g of almonds for 7 days followed by
600 IU/day of all-rac-𝛼-tocopheryl acetate (with no washout
period) [16]. Our sample size was much larger than either
of the previous studies; that is, 𝑛 = 200 individuals (100
each in the ATA and no ATA groups) as compared with 10
vitamin E-supplemented individuals in each prior study (and
noplacebo control groups).Themetabolomic assay platforms
also differed across the three studies. The study comparing
metabolomic profiles in NASH patients who did and did not
respond to vitamin E supplementation also did not identify
any of our top metabolites as being associated with vitamin E
treatment response [18].
Although not formally statistically significant, three
structurally similar amino acids—beta-alanine, ornithine,
and N6-acetyllysine—as well as glutarylcarnitine, decreased
during ATA supplementation. Whether serum changes in
these metabolites are related to the oxidative degradation
of the ATA phytyl side-chain (e.g., through upregulation
of CYP3A activity) or to an effect of the resulting two-
carbon acetyl groups on fatty acid and possibly acetyl-
coenzyme A, metabolism is not known. Exploration of
the pathway(s) through which vitamin E impacted these
biochemical alterations could inform our understanding of
both vitamin E metabolism and the effect of vitamin E on
prostate carcinogenesis.
Strengths of the present analysis include the parent
trial’s randomized controlled design and our measurement of
metabolomics profiles both before and after supplementation
in both the supplemented and unsupplemented groups.
We employed a relatively large sample size, participants
were supplemented for at least a year and an average of
more than three years, and serum was obtained after an
overnight fast. Study limitations included an all Caucasian
male smoker population and the ability to test only one dose
and preparation of 𝛼-tocopherol based on the parent ATBC
trial.
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5. Conclusions
In this analysis of presupplementation versus on-study serum
metabolomic profiles nested within a large controlled trial
of vitamin E, we found the presence of several molecules
that were quantitatively altered by chronic supplementation
with ATA, including two conjugated metabolites of 𝛼-CEHC.
Further study of 𝛼-CEHC and its metabolites in relation to
risk of prostate and other cancers in humans is warranted;
in particular, examination of which enzymes (e.g., CYPs,
UGTs, or sulfatases) may be upregulated during supplemen-
tation with 𝛼-tocopherol. In addition, comparison of pre-
and postsupplementation metabolomic profiles between this
study and other clinical trials of 𝛼-tocopherol supplemen-
tation conducted in different populations or using different
dosages or preparations (e.g., SELECT) may shed light on
the apparently discordant prostate cancer findings across the
trials.
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